6 Dimensions Capital
VC Fund
Shanghai, China
6 Dimensions Capital is a VC fund in Shanghai focused on Biotechnology and Health Care. 6 Dimensions Capital was established in May, 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures. The two prominent and experienced teams formed a healthcare focused investment firm with an in-depth focus and extensive coverage both in China and global market.
- Total investments:
- 51
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $844M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries 6 Dimensions Capital invests in
Stages 6 Dimensions Capital invests in
Countries 6 Dimensions Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 29 (57%)
- Health Care 25 (49%)
- Medical 18 (35%)
- Pharmaceutical 14 (27%)
- Therapeutics 9 (18%)
Stage
- Series B 16 (31%)
- Series A 14 (27%)
- Series C 10 (20%)
- Funding Round 3 (6%)
- Seed 2 (4%)
Country
- United States 20 (39%)
- China 18 (35%)
- Israel 1 (2%)
- Hong Kong 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ching Zhu
Managing Partner
|
Managing Partner | Total investments: 2 | Find email | |
|
Dr. Ge Li
Founding Partner & Chairman
|
Founding Partner & Chairman | Total investments: 0 | Find email | |
|
Edward Hu
Founding Partner
|
Founding Partner | Total investments: 1 | Find email | |
Hannes Thor Smárason
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Lianyong Chen
Managing Partner and CEO
|
Managing Partner and CEO | Total investments: 5 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VFLO Medical
|
VFLO, a medical device startup, to build a cutting-edge medical device platform that would enable Chinese patients to access cutting-edge treatments. Established by a healthcare fund and a team of experienced industry professionals to create a leading medical device platform with a focus on making innovative therapies available to Chinese patients. | $80M / Series B / Dec 03, 2024 | |
MitrAssist
|
MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality.MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valveto work in unison with it and to enhance valve functionality.MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development. | $100M / Series C / Sep 26, 2023 | |
Ignis Therapeutics
|
Ignis Therapeutics is a innovative therapies in the field of central nervous system. | $180M / Series A / Nov 11, 2021 | |
Haoxinqing
|
Haoxinqing is an online medical service platform focusing on the fields of mental psychology and chronic disease management. | $15.7M / Series C / Oct 25, 2021 | |
Exo Therapeutics
|
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential toreprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. | $78M / Series B / Oct 05, 2021 | |
Engine Biosciences
|
Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks includeboth high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. | $43M / Series A / May 26, 2021 | |
Lyvgen Biopharma
|
Lyvgen Biopharma is a cross-linking-dependent antibody platform. The company also provides tumor immune agonistic antibody, local activation of the tumor microenvironment, and synthetic biology engineering services. | $10M / Series C / Feb 23, 2021 | |
TScan Therapeutics
|
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residualleukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. | $100M / Series C / Jan 25, 2021 | |
FogPharma
|
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together withworld-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years. | $107M / Series C / Jan 11, 2021 | |
|
Exo Therapeutics
|
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential toreprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. | $25M / Series A / Dec 16, 2020 | |
| See all 51 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does 6 Dimensions Capital invest in?
6 Dimensions Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 51 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact 6 Dimensions Capital?
Public channels for 6 Dimensions Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 6 Dimensions Capital?
The team at 6 Dimensions Capital includes Ching Zhu (Managing Partner), Dr. Ge Li (Founding Partner & Chairman) and Edward Hu (Founding Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
